Evolving guidelines in the use of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis by Casilda M Balmaceda
Balmaceda BMC Musculoskeletal Disorders 2014, 15:27
http://www.biomedcentral.com/1471-2474/15/27CORRESPONDENCE Open AccessEvolving guidelines in the use of topical
nonsteroidal anti-inflammatory drugs in the
treatment of osteoarthritis
Casilda M BalmacedaAbstract
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are a standard treatment for osteoarthritis (OA), but the
use of oral NSAIDs has been linked to an elevated risk for cardiovascular and gastrointestinal adverse events and
renal toxicity. Topical NSAIDs are thought to afford efficacy that is comparable to oral formulations while reducing
widespread systemic drug exposure, which may provide a benefit in terms of safety and tolerability. As a result,
European treatment guidelines have, for many years, recommended the use of topical NSAIDs as a safe and effective
treatment option for OA. Following the recent approval of several topical NSAID formulations by the US Food and Drug
Administration, US treatment guidelines are increasingly recommending the use of topical NSAIDs as an alternative
therapy and, in some cases, as a first-line option for OA. This commentary summarizes OA treatment guidelines that
are currently available and discusses their potential evolution with regard to the increased inclusion of topical NSAIDs.
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Osteoarthritis (OA) is a chronic, painful, degenerative
joint condition that most commonly affects the hips,
knees, and hands and often requires long-term treatment
to manage acute symptoms and prevent long-term com-
plications. These complications include the destruction of
articular cartilage and subchondral bone, bone remodel-
ling, atrophy of periarticular muscles, capsular stretching,
and synovitis in weight-bearing joints [1]. Additional
health-related problems associated with OA include emo-
tional stress, fatigue, and impaired sleep [2], all of which
may significantly diminish the quality of a patient’s life [3].
Many patients with OA also commonly experience mul-
tiple comorbidities, such as cardiovascular, gastrointes-
tinal, and endocrine disorders [4,5]. OA is estimated to
affect nearly 27 million people in the United States [6],
with annual US healthcare costs stemming from the treat-
ment of OA estimated at $185 billion [7].
Inflammatory processes have been shown to promote
disease progression in OA [8]. Consequently, oral nonste-
roidal anti-inflammatory drugs (NSAIDs) have becomeCorrespondence: casibalmacedamd@gmail.com
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reproduction in any medium, provided the orintegral to the management of OA [9-12]. However, the
use of these agents has been linked to an increase in the
risk of gastrointestinal [13,14], cardiovascular [15,16], and
renal [17,18] adverse events (AEs). The safety of oral
NSAIDs is further compromised with increasing patient
age and by the use of higher doses, extended periods of
use, the presence of comorbid medical conditions, and the
coadministration of certain medications [14,16,19]. Selec-
tive cyclo-oxygenase-2 (COX-2) inhibitors were developed
because they were thought to be safe alternatives for
patients at a greater risk for peptic ulcer disease or gastro-
intestinal bleeding; however, population-based analyses
have called their safety into question [20]. Because COX-2
has substantial expression in cardiovascular and renal
tissue, concerns have been raised regarding potential
adverse cardiovascular and renal effects associated with
the use of these agents [21-24].
Attempts to address these issues have led to the deve-
lopment of new formulations with improved risk-benefit
profiles in relation to earlier generations of NSAIDs. As
a result, a number of NSAIDs are available worldwide as
topical formulations (e.g., ibuprofen, diclofenac, and
ketoprofen). Topical NSAIDs have been shown to pro-
vide analgesia through the same mechanism of action astd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2474/15/27oral NSAIDs, but because the activity of topical NSAIDs
is effectively confined to the application site, systemic
exposure—and consequently, the risk for gastrointes-
tinal, cardiovascular, and renal toxicity—has been shown
to be much lower than that observed with oral NSAIDs
[25-31]. A Cochrane Database review of 34 studies has
demonstrated that topical NSAIDs, in particular those
containing diclofenac, produced fewer systemic AEs
while maintaining similar effectiveness for treating chro-
nic musculoskeletal conditions as compared to oral for-
mulations [32].
This commentary discusses clinical guidelines for the
treatment of OA in the context of the increasing avail-
ability and acceptance of topical NSAIDs in the manage-
ment of OA.
Clinical guidelines for osteoarthritis management
Currently available US guidelines for OA management
include those developed by the American Academy of
Orthopaedic Surgeons (AAOS), the American College
of Rheumatology (ACR), the American Geriatrics
Society (AGS), the American Pain Society (APS), and
the Osteoarthritis Research Society International (OARSI)
[9,12,33-35]. In Europe, the European League Against
Rheumatism (EULAR) and the United Kingdom’s National
Institute for Health and Clinical Excellence (NICE) have
developed OA management guidelines [10,11,36]. Collec-
tively, these guidelines reflect the experience of physicians
across a variety of medical disciplines. However, they differ
in their scope and are reliant on the therapeutic options
that were available at the time they were developed.
Although the groups that formulate these guidelines
generally use the same data sources (i.e., evidence-based
research, expert opinion, patient experience, and cost-ef-
fectiveness analysis), different factors may be considered
by each organization when developing its treatment
recommendations. For instance, the AAOS and AGS
guidelines reflect the perspective of specialists in ortho-
paedic surgery, geriatrics, and pain management, while
the EULAR and OARSI guidelines primarily emphasize
the findings of experts in rheumatology. The NICE
guidelines are developed jointly by physicians and other
healthcare professionals working in conjunction with a
range of clinical researchers. As a result, the guidelines
vary in their emphasis on certain treatment options, and
they may even contradict each other [37]. The scope of
these guidelines tends to vary as well, with some guide-
lines (e.g., AAOS, ACR, EULAR, and OARSI) addressing
specific types of OA (i.e., knee, hip, or hand) and others
(e.g., AGS, APS, and NICE) focusing on OA more
generally.
Table 1 provides a summary of current guidelines re-
garding the use of topical analgesics in the treatment of
OA [9-12,33-36].The NICE guidelines are the first and only to recom-
mend that all patients receive first-line treatment with a
topical NSAID before using an oral NSAID [11]. In the
NICE guidelines, oral NSAIDs, selective COX-2 inhibitors,
and opioids are considered to be adjunctive or second-line
therapies [11]. The positioning of topical NSAIDs in the
NICE guidelines reflects the extensive experience that
physicians in Europe have with topical preparations, as
well as several randomized, controlled trials conducted
with a topical NSAID and placebo, with or without an oral
comparator arm. The results of these studies have demon-
strated that topical NSAIDs improve symptom severity,
daily functioning, and quality of life in adults with OA to a
greater degree than placebo, with results comparable to
the efficacy of oral formulations [38-40]. In addition, NICE
has recently completed the Public Consultation Phase for
developing new guidelines, so an updated version of these
guidelines is expected to be published soon.
The EULAR guidelines for the treatment of hand OA
recommend topical treatments over systemic treatments
[36]. The EULAR (knee OA) guidelines indicate that to-
pical NSAIDs are safe and effective but provide no specific
recommendations regarding their role in the management
of OA [10,35]. OARSI recommends topical NSAIDs only
as second-line or adjunctive therapy in patients whose pain
does not respond to treatment with acetaminophen [12].
Though widely used in Europe, topical NSAIDs have
only recently become available in the United States for
the treatment of OA. The first topical NSAIDs approved
by the US Food and Drug Administration (FDA) were
diclofenac 1% sodium gel, approved in 2007, and diclo-
fenac sodium 1.5% topical solution in 45.5% dimethyl
sulfoxide (DMSO), approved in 2009. Topical NSAIDs
are included in each of the clinical guidelines for the
treatment of OA, with the exception of those put forth
by the APS, which were published in 2002 and thus pre-
ceded the availability of topical NSAIDs in the United
States [34]. Similar to EULAR, the AGS guidelines pro-
vide no specific recommendations regarding the role of
topical NSAIDs in the management of OA [10,35].
The technical expert panel of the ACR concluded in
their recently updated guidelines that topical NSAIDs
should be considered among several first-line therapies for
the treatment of hand or knee OA. In addition, the ACR
specifically recommends the use of topical rather than oral
NSAIDs for patients with hand or knee OA who are
≥75 years of age [9]. Presumably, this age cutoff was
chosen to lower the risk for developing complications re-
lated to the use of oral NSAIDs in an older population,
but the ACR guidelines do not specifically describe the ra-
tionale for making this recommendation.
The AAOS was the first US organization to specifically
recommend topical NSAIDs as a first-line treatment option
in OA. The organization makes a strong recommendation
Table 1 Topical analgesics in osteoarthritis (OA) guidelines
Guideline Recommendation
American Association of Orthopaedic Surgeons (AAOS)
2013 [33]
• Knee OA: Strongly recommend oral or topical NSAIDs or tramadol for the
pharmacologic management of patients with symptomatic OA of the knee
American College of Rheumatology (ACR) 2012 [9] • Hand OA: Initial management of hand OA should include one
• or more of the following:
o topical capsaicin
o topical NSAIDs, including trolamine salicylate
o oral NSAIDs, including COX-2 inhibitors
o tramadol
• Knee OA: Initial management of knee OA should include one





o intra-articular corticosteroid injections
• Topical rather than oral NSAIDs should be used in patients with hand
or knee OA aged ≥75 years
American Geriatric Society (AGS) 2009 [35] • Localized, non-neuropathic persistent pain: Patients with localized,
non-neuropathic persistent pain may be candidates for topical NSAIDs
American Pain Society (APS) 2002 [34] • Guidelines were published prior to FDA approval of topical NSAIDs
European League Against Rheumatism (EULAR) 2003,
2007 [10,36]
• Hand OA: Topical treatments are recommended over systemic treatments,
especially for mild to moderate pain and when only a few joints are affected
• Hand or Knee OA: Topical NSAIDs and capsaicin have clinical efficacy and are
safe in the treatment of hand or knee OA
National Institute for Health and Clinical Excellence
(NICE, United Kingdom) 2008 [11]
• Hand or Knee OA:
o Topical NSAIDs should be considered for pain relief in addition to
nonpharmacologic treatment
o Topical NSAIDs and/or acetaminophen should be considered ahead
of oral NSAIDs, COX-2 inhibitors, or opioids
Osteoarthritis Research Society International (OARSI)
2008 [12]
• Knee OA: Topical NSAIDs and capsaicin may be effective as adjunctives and
alternatives to oral analgesics/anti-inflammatory agents in patients with knee OA
AAOS = American Association of Orthopaedic Surgeons; ACR = American College of Rheumatology; AGS = American Geriatric Society; APS = American Pain Society;
COX = cyclo-oxygenase; EULAR = European League Against Rheumatism; FDA = US Food and Drug Administration; GI = gastrointestinal; NICE = National Institute for
Health and Clinical Excellence; NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis; OARSI = Osteoarthritis Research Society International.
Adapted from Hochberg MC et al. Arthritis Care Res (Hoboken) 2012, 64:465-474; Jordan KM et al. Ann Rheum Dis 2003, 62:1145-1155; National Collaborating
Centre for Chronic Conditions. Osteoarthritis: National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians; 2008; Zhang W
et al. Osteoarthritis Cartilage 2008, 16:137-162; Treatment of Osteoarthritis of the Knee Evidence-Based Guideline 2nd Edition. Rosemont, IL: American Academy of
Orthopaedic Surgeons; May 2013; Simon LS et al. Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis, 2nd
edition. Clinical Practice Guidelines no. 2. Glenview, IL: American Pain Society; 2002; American Geriatrics Society Panel on the Pharmacological Management of
Persistent Pain in Older Persons. J Am Geriatr Soc 2009, 57:1331-1346; Zhang W et al. Ann Rheum Dis 2007, 66:377-388.]
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pharmacologic treatment options for the management of
OA of the knee [33]. Interestingly, these guidelines deter-
mined that the data available for acetaminophen, opioids,
and pain patches was inconclusive regarding their efficacy
for treating OA of the knee.
Recommendations for future research and guideline
development
As the amount of data available in the literature support-
ing the efficacy and safety of topical NSAIDs continues togrow, treatment guidelines can be expected to evolve as
well. Several double-blind, randomized clinical trials have
been published that support the recent shift in US-based
guidelines to include the FDA-approved topical NSAIDs
as first-line agents.
In two of these studies, patients with OA were treated
with topical diclofenac sodium 1% gel. One study was
8 weeks in duration and enrolled patients with OA of
the hand, while the other, a 12-week study, enrolled pa-
tients with OA of the knee. In both of these studies,
topical diclofenac sodium 1% gel produced significant
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tive to placebo as early as the end of treatment week 1,
with continued improvement over the course of the
studies [41].
In another study, patients with OA of the knee were
treated using diclofenac sodium 1.5% topical solution in
45.5% DMSO for 12 weeks. Topical diclofenac produced
significant improvement compared with placebo on mea-
sures of pain and physical functioning, as well as patient
global assessment. The topical diclofenac arm of this study
produced a treatment effect that was comparable to slow-
release oral diclofenac [42].
Recent analyses of short-term clinical trials conducted
with topical NSAIDs suggest that this class of treatment
may be a preferred monotherapy option for patients
with OA in single or multiple superficial joints, parti-
cularly among those who are at an increased risk for
NSAID-related systemic AEs [25-28]. In a longer-term,
12-month, post hoc analysis conducted in patients with
OA of the knee stratified by age (ie, <65 or ≥65 years)
and treated with diclofenac sodium 1% gel, the overall
rates of gastrointestinal and cardiovascular AEs were
generally similar for both age groups [43]. The true
safety profile of topical NSAIDs can only be determined
after many years of use in a large patient population.
Therefore, long-term, head-to-head trials comparing the
efficacy and safety of topical versus oral NSAIDs may be
necessary. Future research should also include patients
with OA involving multiple joints and comorbid condi-
tions to confirm the safety of topical NSAIDs in patients
who may have the highest risk for developing tolerability
issues.
Clinical guidelines on the use of topical NSAIDs as safe
and effective alternatives to oral NSAIDs should be re-
gularly evaluated as new OA research emerges. Many
current treatment guidelines for OA already suggest mi-
nimizing NSAID exposure and the risk of complications
by prescribing the lowest effective oral dose for the shor-
test duration of time, but initiating treatment with topical
NSAIDs, as recommended in the NICE guidelines, may
help to even more effectively mitigate such risks. If long-
term tolerability data demonstrate that there is a signifi-
cant reduction in the frequency of cardiovascular and
gastrointestinal AEs with topical NSAIDs compared to
oral NSAIDs, revising or removing the black box warning
requirement for topical NSAIDs also may be warranted.
Conclusions
Currently, only the NICE and AAOS recommend topical
NSAIDs as first-line treatment for OA of the knee. Ad-
ditionally, EULAR guidelines recommend these agents
as a first-line option for OA of the hand. Other guide-
lines, such as ACR, recommend topical NSAIDs as
first-line treatment only for select, high-risk patientpopulations. However, several US guidelines have not
been updated since the recent FDA approval of topical
diclofenac formulations. Reevaluation of those guidelines
on the basis of emerging research should help to stream-
line OA management recommendations and further im-
prove patient outcomes in the safest possible manner.
Recommendations for the management of OA will likely
continue to evolve to include the increased and earlier
use of topical NSAIDs.
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